Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.2% during the 4th quarter, Holdings Channel reports. The firm owned 2,969 shares of the pharmaceutical company’s stock after buying an additional 436 shares during the period. Avior Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,196,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Czech National Bank lifted its position in shares of Vertex Pharmaceuticals by 6.2% during the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after purchasing an additional 3,260 shares in the last quarter. Whalen Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $662,000. Creative Planning lifted its position in shares of Vertex Pharmaceuticals by 5.3% during the second quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after purchasing an additional 3,998 shares in the last quarter. Mizuho Securities USA LLC raised its holdings in Vertex Pharmaceuticals by 289.0% in the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after acquiring an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in Vertex Pharmaceuticals by 19.4% in the fourth quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after acquiring an additional 55,739 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $439.62 on Friday. The firm’s fifty day moving average price is $435.88 and its 200 day moving average price is $464.95. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The firm has a market cap of $113.22 billion, a price-to-earnings ratio of -220.91, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the company earned $3.67 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several analyst reports. Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Bank of America reduced their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a report on Thursday, December 19th. UBS Group raised their target price on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Truist Financial reduced their target price on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $494.84.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.